Le Lézard
Classified in: Health
Subjects: PDT, FDA

ESPEROCT® is now approved in Canada for the Treatment of Hemophilia A in both Children and Adults


New treatment can help Canadians living with hemophilia A better manage their bleeding episodes

TORONTO, July 12, 2019 /CNW/ - Novo Nordisk announced today that Health Canada has approved ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) for use in adults and children with hemophilia A (congenital Factor VIII deficiency) for:

Novo Nordisk (CNW Group/Novo Nordisk Canada Inc.)

 "Canadians living with hemophilia A are at risk of bleeding for longer periods of time. If not treated appropriately, those bleeding episodes, particularly into joints and muscles, can be painful, lead to joint damage and muscular atrophy over the patient's lifetime and in some cases can be life threatening," said Dr. Anthony Chan, OOnt, Professor of Paediatrics, McMaster University. "ESPEROCT® has been shown to be effective in reducing the risk of bleeding episodes among patients." 

Health Canada's approval is based on the findings from three multinational, open-label, non-controlled trials in male subjects with severe hemophilia A, which is defined as having less than 1 per cent of the normal level of factor VIII in the blood.2,3 All subjects were previously treated, having received other FVIII products for more than 150 exposure days for adolescents and adults and more than 50 exposure days for pediatric subjects.4

"The Canadian Hemophilia Society advocates for access to the widest possible range of coagulation therapies and welcomes the regulatory approval of this additional option for the treatment of hemophilia A," said Paul Wilton, President, Board of Directors, Canadian Hemophilia Society.

Overall, ESPEROCT® was shown to provide effective prophylaxis and maintain a low median ABR of 1.18 when dosed at 50 IU/kg every 3-4 days in adults and adolescents (those aged 12 years and over) and a median ABR of 1.95 in children under 12 years of age when dosed twice weekly at 60 IU/kg (50-75 IU/kg).5

Across the clinical trials and age groups, ESPEROCT® was well tolerated and had no safety concerns identified.6 The safety profile of ESPEROCT® is similar to what has been reported for other long-action FVIII products.7

About Hemophilia A

Hemophilia A is an X-linked, recessive disorder caused by a deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation.8 One out of three cases for the estimated 2,500 Canadians living with hemophilia A are caused by a new genetic mutation. 9,10 The most common symptom associated with hemophilia is a bleeding problem, which can lower the overall quality of life for many patients.11

About ESPEROCT®

ESPEROCT® (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A. In adults, the half-life for ESPEROCT® was determined to be 19 hours compared to 12 hours for unmodified FVIII products, using the chromogenic assay.12

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries, and markets its products in more than 170 countries. For more information, visit novonordisk.ca, Twitter and YouTube.

References:
________________________________
1 ESPEROCT® Product Monograph, July 4, 2019
2 ESPEROCT® Product Monograph, July 4, 2019
3 Canadian Hemophilia Society. What is hemophilia? Available https://www.hemophilia.ca/what-is-hemophilia/. Accessed on July 2, 2019.
4 ESPEROCT® Product Monograph, July 4, 2019
5 ESPEROCT® Product Monograph, July 4, 2019
6 ESPEROCT® Product Monograph, July 4, 2019
7 ESPEROCT® Product Monograph, July 4, 2019
8 Canadian Hemophilia Society. Hemophilia A and B. Available https://www.hemophilia.ca/hemophilia-a-and-b/. Accessed on June 27, 2019
9 Canadian Hemophilia Society. Hemophilia A and B. Available https://www.hemophilia.ca/hemophilia-a-and-b/. Accessed on June 27, 2019
10 Health Sciences North. Welcome to the Hemophilia Program. Available https://www.hsnsudbury.ca/portalen/Programs-and-Services/Community-Care-and-Rehabilitation/Hemophilia. Accessed on June 27, 2019
11 Health Sciences North. Welcome to the Hemophilia Program. Available https://www.hsnsudbury.ca/portalen/Programs-and-Services/Community-Care-and-Rehabilitation/Hemophilia. Accessed on June 27, 2019
12 ESPEROCT® Product Monograph, July 4, 2019

SOURCE Novo Nordisk Canada Inc.


These press releases may also interest you

at 17:04
Healthfirst, New York's largest not-for-profit health insurance companyi with more than 1.4 million members, is excited to announce the opening of its first location in the Mid-Hudson Valley and to cement its presence in Orange County. The newly...

at 17:02
Shopko Optical, a leading provider of quality eye care services to communities for over 40 years, is pleased to announce the opening of 80 free-standing optical centers in 180 days! Continuing its dramatic growth, Shopko Optical is planning to open...

at 17:01
Valens expands exclusive licence for S?RSE cannabis emulsion technology to include Europe, Australia and Mexico in addition to CanadaAmendment represents a nearly 20x increase in the addressable population exclusively available to Valens and its...

at 17:00
Invesque Inc. announced today a cash dividend in the amount of US$0.06139 per common share for the period from December 1, 2019 to December 31, 2019. The dividend will be payable on January 15, 2020 to shareholders of record as of December 31, 2019....

at 16:58
Laminate Medical Technologies (Laminate) has announced the completion enrollment of the VALUE study for the VasQtm External Support. The post-market study enrolled 80 patients (50 upper arm and 30 forearm fistulas) for sites across Germany, France,...

at 16:42
Danaher Corporation announced today the final exchange ratio for its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation...



News published on 12 july 2019 at 07:00 and distributed by: